Analyst Research Roundup: ADOMANI, Inc. (ADOM), CorMedix, Inc. (CRMD)

ADOMANI, Inc. (NASDAQ:ADOM) tinted loss of -1.51% (0 points) to US$0.32. The volume of 1.51 Million shares climbed down over an trading activity of 359.67 Million shares. EPS ratio determined by looking at last 12 month figures is -0.14. Over the same time span, the stock marked US$1.97 as its best level and the lowest price reached was US$0.16. The corporation has a market cap of US$24.88 Million.

ADOMANI, Inc. (NASDAQ:ADOM)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -126.9 percent while most common profitability ratio return on investment (ROI) was -490.9 percent. The company’s institutional ownership is monitored at 3.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

CorMedix, Inc. (NYSE:CRMD) is worth US$269.16 Million and has recently fallen -7.92% to US$2.44. The latest exchange of 7.37 Million shares is above its average trading activity of 2.69 Million shares. The day began at US$2.71 but the price moved to US$2.42 at one point during the trading and finally capitulating to a session high of US$2.71. The stock tapped a 52-week high of US$2.72 while the mean 12-month price target for the shares is US$4.75.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 538.32. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -15.1%. With an institutional ownership near 18.8%, it carries an earnings per share ratio of -0.5.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.